Medicare GLP-1 Coverage in 2026: What Part D Actually Pays For

Medicare GLP-1 coverage runs on one rule with a growing list of exceptions. The rule, written into the law that created Part D: Medicare may not pay for drugs used for weight loss. The exceptions: every other thing GLP-1s treat — type 2 diabetes, cardiovascular risk, obstructive sleep apnea, liver disease — is coverable. And as of July 1, 2026, a federal demonstration program pays for weight loss itself, $50 a month, for the first time in Medicare's history.

Direct answer: In 2026, Medicare Part D covers GLP-1s prescribed for type 2 diabetes (Ozempic, Mounjaro, Rybelsus, Trulicity, Victoza), Wegovy for cardiovascular risk reduction in adults with heart disease plus overweight/obesity, Zepbound for moderate-to-severe obstructive sleep apnea, and Wegovy for noncirrhotic MASH. It does not cover any GLP-1 prescribed purely for weight loss — that statutory exclusion has stood since Part D launched in 2006. The carve-out arrives July 1, 2026: the Medicare GLP-1 Bridge, a demonstration running through December 31, 2027, covers Wegovy, the Zepbound KwikPen, and Foundayo for weight management at a flat $50/month for beneficiaries meeting BMI criteria. Coverage of everything else still varies plan by plan, with prior authorization nearly everywhere.

The scale explains the fight over all this: Medicare processed 21.8 million GLP-1 claims totaling $27.5 billion in gross spending in 2024 — before covering weight loss at all.

Medicare GLP-1 Coverage at a Glance (2026)

GLP-1 Drugs Medicare Part D Covers for Type 2 Diabetes

This is the unglamorous bulk of Medicare GLP-1 coverage. Every diabetes-labeled GLP-1 is coverable under Part D, and most plans carry at least Ozempic, Mounjaro, Rybelsus, and Trulicity — typically on a preferred or non-preferred brand tier with prior authorization confirming a type 2 diabetes diagnosis. What you pay depends on your plan's tiers and where you are in the benefit year, but two systemwide protections apply in 2026:

• The $2,100 out-of-pocket cap. Once your total Part D out-of-pocket spending hits $2,100, you pay $0 for covered drugs the rest of the year.
• Negotiated prices are coming. Semaglutide (Ozempic, Rybelsus, Wegovy) was selected in the second round of Medicare drug price negotiation; a CMS fact sheet from November 2025 set the negotiated price at $274/month, effective 2027 — down from a list price near $1,000.

One quirk worth knowing: Medicare covers the indication, not the molecule. Tirzepatide is covered as Mounjaro for diabetes but was not covered as Zepbound for weight loss — same drug, different label, opposite coverage. More background in our GLP-1 insurance coverage guide.

Why Medicare Excludes Weight-Loss Drugs (and Always Has)

When Congress wrote the Part D statute, it imported a list of excludable drug categories from Medicaid law — cosmetic drugs, fertility drugs, and "agents when used for anorexia, weight loss, or weight gain." That made the exclusion statutory: no Part D plan could cover Wegovy for obesity even if it wanted to, and no CMS regulation could change it. A proposed Biden-era rule to reinterpret obesity as a disease (rather than "weight loss" use) was never finalized.

That's why everything that's happened since 2024 has come through side doors: new FDA indications that aren't "weight loss," and now a demonstration program that operates outside Part D entirely.

Medicare and GLP-1 Coverage 2026: The Carve-Out Indications

Three FDA label expansions turned weight-loss drugs into Part D-coverable drugs for specific patients:

These pathways share a pattern: coverage is legally possible but operationally narrow. Plans demand documentation of the qualifying diagnosis, and the prescription must be written for that indication. CMS explicitly requires plans to run formulary-exception processes for these drugs rather than steering patients elsewhere.

The Medicare GLP-1 Bridge: $50/Month Weight-Loss Coverage From July 2026

The genuinely new piece of Medicare GLP-1 coverage in 2026. Born from the November 6, 2025 White House pricing deal with Novo Nordisk and Eli Lilly, the Bridge is a CMS-run demonstration — outside Part D — that covers Foundayo (all forms), Wegovy (all forms), and the Zepbound KwikPen for weight management at a flat $50/month copay, with manufacturers supplying drugs at a $245 negotiated net price. It runs July 1, 2026 through December 31, 2027.

The compressed version: you must be 18+, in an eligible Part D or Medicare Advantage drug plan, and meet a BMI tier (≥35 alone; ≥30 with certain heart/kidney conditions; ≥27 with pre-diabetes or established vascular disease) measured at the time you started GLP-1 therapy. Your doctor files prior authorization with a CMS central processor — no beneficiary sign-up. The $50 never counts toward your deductible or the $2,100 cap, and Extra Help doesn't reduce it. People whose GLP-1 indication is Part D-coverable (diabetes, OSA, MASH, CV) are excluded.

Full eligibility tables, drug list, and enrollment steps: Medicare GLP-1 Bridge program guide.

Medicare GLP-1 Coverage Varies Plan by Plan

Even for fully coverable indications, your experience depends on your specific PDP or Medicare Advantage drug plan:

• Formulary inclusion — a plan may cover Ozempic but not Mounjaro, or carry Zepbound for OSA while a competitor doesn't.
• Tier placement — preferred vs. non-preferred brand tiers can mean a 25% vs. 40%+ coinsurance difference before the cap.
• Prior authorization and step therapy — nearly universal for GLP-1s; some plans require trying metformin or documenting A1C first.
• Annual changes — formularies reset every January; a covered drug can be dropped or re-tiered. Check during open enrollment (October 15 - December 7) using Medicare's plan finder.

How to Appeal a Medicare GLP-1 Denial

If your prescription is for a coverable indication and the plan says no:

1. Request a coverage determination (and a formulary exception if the drug isn't listed), with a supporting statement from your prescriber tying the prescription to the FDA-approved indication.
2. File a redetermination — the first-level appeal — within 65 days of a denial.
3. Escalate to the Independent Review Entity (IRE) if the plan upholds its denial; further levels (ALJ hearing and beyond) exist for high-cost disputes.

Appeals succeed most often when the paperwork makes the qualifying diagnosis impossible to miss: the diabetes diagnosis code, the sleep study, the cardiac history. A prescription that looks like weight-loss treatment in disguise will lose.

If Medicare Won't Cover Your GLP-1

Until July 2026 — or if you miss the Bridge's BMI tiers or sit in an ineligible plan type — your realistic options are cash programs, since manufacturer savings cards exclude all government beneficiaries. LillyDirect and NovoCare sell direct: Foundayo and oral Wegovy from $149/month, Zepbound KwikPens $299-$449, Wegovy pens from $349. Comparison shopping lives in our cheapest GLP-1, Wegovy coupon, and Zepbound coupon guides.

On Medicare but locked out until July — or not eligible at all? Yücca telehealth — online evaluation, doctor-prescribed compounded Semaglutide+ or Tirzepatide+ filled by a licensed US pharmacy, from $146/month, no insurance involved. (Partner link: we may earn a commission, at no extra cost to you.)

Frequently Asked Questions

Does Medicare cover GLP-1 drugs in 2026? Yes, for specific indications: type 2 diabetes (Ozempic, Mounjaro, Rybelsus, Trulicity), cardiovascular risk reduction (Wegovy), obstructive sleep apnea (Zepbound), and noncirrhotic MASH (Wegovy). For weight loss alone, only through the GLP-1 Bridge demonstration starting July 1, 2026.

Does Medicare cover Ozempic? Yes — for type 2 diabetes, through Part D, on most plan formularies with prior authorization. Not for weight loss, and Ozempic is not one of the three Bridge program drugs.

Does Medicare cover Wegovy in 2026? Through Part D only for cardiovascular risk reduction or MASH. For weight loss, Wegovy (pen and tablets) is covered at $50/month under the GLP-1 Bridge from July 1, 2026 — wegovy.com confirms the $50 Medicare price for all doses.

Why doesn't Medicare cover weight-loss drugs? The Part D statute imported Medicaid's excludable-drug categories, which include agents used for weight loss. Changing it permanently requires Congress; the Bridge sidesteps it temporarily as a demonstration program ending December 31, 2027.

Will GLP-1 prices on Medicare come down? They already are: the November 2025 deal set a $245 Medicare net price for the Bridge drugs, and negotiated semaglutide prices ($274/month per the November 2025 CMS fact sheet) take effect in Part D in 2027.

Does Medicare Advantage cover GLP-1s differently than Part D? The same indication rules apply — MA drug coverage is Part D coverage. The main differences are formulary and prior-auth strictness, and Bridge eligibility: only HMO, HMO-POS, and local/regional PPO MA-PD plans qualify for the Bridge.

Last reviewed: June 13, 2026

Sources

• Medicare GLP-1 Bridge: Information for Medicare Beneficiaries — CMS
• Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries — CMS Newsroom
• What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge — KFF
• What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries — KFF
• Does Medicare Cover Zepbound for Sleep Apnea? — SleepApnea.org
• White House Strikes GLP-1 Pricing Deal With Lilly, Novo — BioSpace
• What Medicare Drug Price Negotiation Means for You — GoodRx
• Save on Wegovy — wegovy.com
• Zepbound Coverage and Savings — zepbound.lilly.com